201. Real-World Characteristics of Patients with Severe Asthma prior to Starting Dupilumab: The ProVENT Study.
- Author
-
Korn, Stephanie, Schmidt, Olaf, Timmermann, Hartmut, Watz, Henrik, Gappa, Monika, Radwan, Amr, De Prado Gómez, Lucia, Atenhan, Anne, Barbus, Sebastian, Thakur, Mayank, and Lommatzsch, Marek
- Subjects
DRUG therapy for asthma ,THERAPEUTIC use of monoclonal antibodies ,BIOMARKERS ,EOSINOPHILS ,ASTHMA ,ADRENOCORTICAL hormones ,TREATMENT effectiveness ,RESEARCH funding ,NITRIC oxide ,ALLERGENS ,PHENOTYPES ,LONGITUDINAL method ,COMORBIDITY ,SYMPTOMS - Abstract
Introduction: Dupilumab is approved for the treatment of severe type 2 (T2) asthma; however, the characteristics of patients receiving dupilumab in routine clinical practice are incompletely understood. This study describes the characteristics of patients with severe asthma before dupilumab treatment in a real-world setting. Methods: This interim analysis of an ongoing real-life study of dupilumab assessed baseline characteristics of the first patient cohort enrolled in the ProVENT study. Results: A total of 99 patients (59% females) were analyzed (17% received another biologic before dupilumab treatment and 15% were on maintenance oral corticosteroid treatment). Adult-onset asthma (>18 years) and an allergic phenotype were documented in 58% and 48% of patients, respectively. Median (interquartile range) age was 54 (40–61) years; the median number of exacerbations in the last 24 months was 1 (0–3); median fractional exhaled nitric oxide (FeNO) value was 38 (23–64) ppb; and median blood eosinophils (bEOS) count was 184 (8–505) cells/µL. According to the United Kingdom Severe Asthma Registry classification, 53% of patients had T2 intermediate asthma (bEOS ≥150 cells/µL or FeNO ≥25 ppb), 17% had T2 high asthma (bEOS ≥150 cells/µL and FeNO ≥25 ppb), and 4% had T2 low asthma (bEOS <150 cells/µL and FeNO <25 ppb). At least one GINA criterion for T2 airway inflammation was documented in 70% of patients. T2 comorbidities were observed in 64% of patients. Conclusions: This analysis suggests that patients eligible for dupilumab treatment display various clinical and biochemical characteristics rather than one clear-cut phenotype. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
